Writing in the July issue of the journal, Dr Nimish Vakil and colleagues looked at the ideal duration of Helicobacter pylori eradication treatment for patients in the USA, and examined whether eradication therapy is as successful in non-ulcer dyspepsia patients as in those with peptic ulcer disease.
They compared the efficacy of 3-, 7-, and 10-day triple therapies with rabeprazole to a 10-day omeprazole control triple therapy in both patients with and without peptic ulcer disease.
The multicenter, double-blinded randomized, parallel-group trial included 803 patients with H. pylori as determined by [13C]urea breath test and rapid urease test or culture.
Each patient received either rabeprazole, 20 mg bd, amoxicillin 1000 mg bd and clarithromycin 500 mg bd for 3, 7, or 10 days, or else 10 days of omeprazole 20 mg bd, with the same antibiotic regimen (control).
|Eradication results were similar with 7- or 10-day therapies|
|Alimentary Pharmacology & Therapeutics|
6 weeks after completion of treatment, H. pylori status was reassessed by [13C]urea breath test, as before.
Eradication percentages achieved in intent-to-treat patients with rabeprazole-based treatments were 27%, 77% and 78% respectively for the 3-, 7-, and 10-day courses.
In the case of the omeprazole-based therapy, eradication was achieved in 73% of patients.
There was no statistically significant difference between the 7-day rabeprazole-based regimen and the 10-day rabeprazole- and omeprazole-based regimens.
"Seven-day therapy with rabeprazole, clarithromycin, and amoxicillin is similar in efficacy to 10-day therapies and had similar efficacy in patients with and without ulcer disease", conclude the authors of the report.